This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.

UPC dismisses Abbott's appeal of Powell's access to pleadings in Sibionics dispute

( January 9, 2025, 15:00 GMT | Official Statement) -- MLex Summary: The UPC Court of Appeal dismissed Abbott Diabetes Care Inc.’s appeal against the lower court's decision granting Powell Gilbert LLP access to pleadings in its patent dispute with Sibionics concerning EP 2,713,879 and EP 3,831,283. Powell Gilbert, acting in the public interest, sought access, emphasizing the need for transparency in the UPC system. Abbott opposed the request, arguing that releasing the documents would compromise procedural integrity and sensitive information. However, the Court of Appeal upheld the original ruling and said that due to the public interest the access is permissible....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections